Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome
Bo Gao(Sun Yat-sen University), Anna DeFazio(The University of Sydney), David D.L. Bowtell(The University of Melbourne), Kathryn Alsop(Peter MacCallum Cancer Centre), Catherine J. Kennedy(The University of Sydney), Sián Fereday(Peter MacCallum Cancer Centre), Kristina Lindemann(Norwegian Cancer Society), Paul R. Harnett(The University of Sydney), Richard W. Tothill(The University of Melbourne), Rosemary L. Balleine(The University of Sydney), Lyndal Anderson(The University of Sydney), Jillian A. Hung(Millennium Institute), Val Gebski(The University of Sydney)
Cited by 17
Related Papers
Pan-cancer analysis of whole genomes
|Nature|2020|3.3k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas
|New England Journal of Medicine|2010|1.7k
Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
|Clinical Cancer Research|2008|1.5k